US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04356339|
Recruitment Status : Not yet recruiting
First Posted : April 22, 2020
Last Update Posted : November 17, 2020
In this study researchers want to learn more about the medication usage behavior among multiple sclerosis (MS) patients treated with BETASERON using the myBETAapp. Multiple sclerosis (MS) is a disease in which the covering called "myelin" around the nerves of the central nervous system degenerate. MS is a lifelong disease therefore requiring continuous treatment to delay the disease progression and reduce the rate of relapse (the return of signs and symptoms of). BETASERON is an approved medicine used to reduce the relapse in patients with MS. It is injected into the tissue under the skin using BETACONNECT autoinjector, which automatically captures injection data including injection date, time, speed, and depth and uploads the data into paired myBETAapp. This allows patients to organize and track their progress and share the injection information with their physicians. The medication usage behavior to be collected in this study includes the elements to what extent
- taking medication matches the presciber's recommendation (adherence, compliance),
- treatment for the prescribed duration (persistence) is continued and
- injections were missed. Among MS patients treated with Betaferon using the myBETAapp the study will also collect information on the health-related quality of life , treatment satisfaction and satisfaction with treatment support.
|Condition or disease||Intervention/treatment|
|Multiple Sclerosis||Drug: Interferon-beta-1b (BETASERON, BAY 86-5046)|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||US PROmyBETAapp2.0: Ascertaining Medication Usage and Patient-reported Outcomes (PROs) Via the myBETAapp™ in Patients With Multiple Sclerosis Treated With BETASERON® Using BETACONNECT™ Autoinjector|
|Estimated Study Start Date :||November 15, 2020|
|Estimated Primary Completion Date :||February 3, 2021|
|Estimated Study Completion Date :||March 31, 2021|
Participants with Multiple Sclerosis treated with BETASERON using BETACONNECT autoinjector and myBETAapp will be enrolled
Drug: Interferon-beta-1b (BETASERON, BAY 86-5046)
Using the BETACONNECT autoinjector and myBETAapp as prescribed by the physician
- Compliance to therapy [ Time Frame: Up to 6 months ]Compliance is defined as the the proportion of BETASERON administrations with the correct injection interval within some window. Windows will be set for each individual patient based on prescribed injection frequency.
- Persistence of therapy [ Time Frame: Up to 6 months ]Persistence to BETASERON using the BETACONNECT device will be measured as the number of days between the initial BETASERON administration and the earlier of the last BETASERON administration using the BETACONNECT device or before a minimum 60-day gap in therapy.
- Adherence to therapy [ Time Frame: Up to 6 months ]Adherence to BETASERON using the BETACONNECT device is a dichotomous variable (adherent or non-adherent) defined as receiving at least 80% of the expected number of injections during 6 months of treatment (or up to the point of early termination) as captured by the BETACONNECT device.
- Change in patient-reported health-related quality of life (HRQOL) [ Time Frame: Up to 6 months ]Change in patient-reported health-related quality of life (HRQOL) will be collected via an online study-specific patient survey.
- Patient satisfaction with the myBETAapp [ Time Frame: Up to 6 months ]Patient satisfaction with the myBETAapp will be collected via an online study-specific patient survey.
- Change in health status evaluated by EQ-5D-5L descriptive system [ Time Frame: Up to 6 months ]EQ-5D-5L is a standardized measure of general health status. The EQ-5D-5L descriptive system consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), where respondents indicate their health state on each dimension based on 5 response options (no problems, slight problems, moderate problems, severe problems, and extreme problems).
- Change in EQ-Visual Analog Score (EQ-VAS) [ Time Frame: Up to 6 months ]The EQ-Visual Analog Score (EQ-VAS) allows respondents to rate their health on a 20 cm vertical, visual analog scale with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine' and provides a single quantitative measure of health.
- Change in prescription and non-prescription medication usage [ Time Frame: Up to 6 months ]Prescription and non-prescription medication usage will be collected via an online study-specific patient survey.
- Number of relapses [ Time Frame: Up to 6 months ]
- Number of participants with treatment with corticosteroids due to relapses [ Time Frame: Up to 6 months ]
- Number of emergency room visits due to relapse [ Time Frame: Up to 6 months ]
- Number of hospitalizations due to relapse [ Time Frame: Up to 6 months ]
- Patient self-assessment [ Time Frame: Up to 6 months ]Self-assessment includes assessment for mood, memory, vision, urinary symptoms. The assessment will be collected via an online study-specific patient survey.
- Change in dose of BETASERON prescription [ Time Frame: Up to 6 months ]
- Change in frequency of BETASERON prescription [ Time Frame: Up to 6 months ]
- Patient satisfaction with the BETACONNECT autoinjector [ Time Frame: Up to 6 months ]Patient satisfaction with the BETACONNECT autoinjector will be collected via an online study-specific patient survey.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04356339
|Contact: Bayer Clinical Trials Contact||(+)1-888-84 firstname.lastname@example.org|
|United States, New Jersey|
|Whippany, New Jersey, United States, 07981|